ClinicalTrials.gg
RecruitingNCT04412187ICARUSUpdated Apr 4, 2025

Inflammatory faCtors AfteR acUte Ischemic Stroke

An interventional study of [18F]-GE-180 PET and 3T MRI in Ischemic Stroke, sponsored by Martin Dichgans. Recruiting at 2 sites in Germany. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Martin Dichgans · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Ischemic Stroke with a site in Germany — 41 open to participants now, 50 under way, 5 of them phase 3. Ischemic Stroke · Germany.

Planned enrollment
89th of 101
36 · median 223
Started
2020
with 6 others
No phase
45 of 164
13 open now
Primary completion
2026-12
later than 19 of 49 live
Registered
105th of 164
by date

Among the 164 studies in Ischemic Stroke with a site in Germany, this one is the 89th largest by planned enrollment of the 101 interventional ones that give a count, is one of 7 that started in 2020, is one of 45 with no phase, reaches primary completion later than 19 of the 49 other live ones, and was the 105th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

41 of the 164 studies in Ischemic Stroke with a site in Germany are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Ischemic Stroke with a site in Germany, or all of them as a file.
02

Study summary

ICARUS is an interventional single-centre hospital-based cohort study in patients admitted to the stroke unit with an acute ischemic stroke. The aims of the study are to i) define the characteristics and determinants of microglial activation after human stroke, and ii) assess the correlation of microglial activation with circulating inflammatory markers, structural brain changes on neuroimaging, and neurological outcomes.

ICARUS involves serial TSPO-PET imaging along with serial MRI, immune cell profiling in blood, and both clinical and laboratory assessments in 36 patients with acute ischemic stroke caused by a cortical (N=18) or strictly subcortical (N=18) infarct.

In a substudy, the investigators will include 10 independently recruited patients with acute ischemic stroke to assess MRI arterial spin labelling (ASL) sequences as a marker for perfusion measurement of the TSPO tracer.

Read the detailed description

The neuroinflammatory response after ischemic brain injury has been identified as a pathomechanism in ischemic stroke. Stroke induces an activation of microglia in the brain, which lasts over months. However, the characteristics and mechanisms of this microglia activation are insufficiently defined.

Our study hypotheses are (i) that a subpopulation of patients with acute stroke develop prominent microglial activation, and (ii) that patients with extensive microglial activation are more likely to experience poor outcome.

Against this background, the investigators set up the "Inflammatory faCtors AfteR acUte ischemic Stroke (ICARUS)" study as an interventional single-centre hospital-based cohort study. N=36 patients with a cortical (N=18) or strictly subcortical (N=18) acute ischemic stroke will be recruited through the local stroke unit (Department of Neurology, LMU Munich). Study participation involves serial TSPO-PET imaging along with serial MR imaging, immune cell profiling in blood, and both clinical and laboratory assessments. Follow-up assessments at 3 weeks, 3 months, 6 months and 12 months will be conducted at the Institute for Stroke and Dementia Research (ISD) and at the Department of Nuclear medicine, both LMU Munich.

In a substudy, the investigators will include 10 independently recruited patients with acute ischemic stroke to assess MRI arterial spin labelling (ASL) sequences as a marker for perfusion measurement of the TSPO tracer. These patients will receive dynamic PET in addition to the ASL sequences.

03

Conditions studied

  • Ischemic Stroke

Keywords

  • microglia
  • neuroinflammation
  • functional outcome after stroke
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years
  • Acute ischemic stroke (time frame: \<72 hours) as defined by an acute focal neurological deficit in combination with a corresponding infarct as documented by a diffusion weighted imaging (DWI)-positive lesion on magnetic resonance imaging (MRI); presence of an infarct involving the cortex or a strictly subcortical infarct
  • Written prior to study participation
  • Willingness to participate in study assessments including follow-up

Exclusion criteria

Exclusion Criteria:

  • Unwillingness or inability to give written consent
  • Prior history of stroke, multiple infarcts, infratentorial infarcts affecting the brain stem or cerebellum
  • Known diseases of the CNS other than stroke
  • Immunomodulatory therapies within the last 3 months prior stroke
  • Chronic inflammatory disease
  • Infectious diseases within the last 7 days prior stroke
  • Conditions interfering with follow-up such as end-stage
  • for MRI or PET (pacemaker, aneurysm clip, cochlear implant etc.)
  • Radiation exposure of > 10mSv per year
  • Pregnant or breastfeeding women
  • Participation in a clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Other
    TSPO PET imaging

    All study participants will receive \[18F\]-GE-180, i.e. TSPO PET imaging to assess microglia activation.

    Diagnostic Test: [18F]-GE-180 PET · Diagnostic Test: 3T MRI · Diagnostic Test: immune cell profiling in blood

Interventions

  • Diagnostic test[18F]-GE-180 PET

    serial \[18F\]-GE-180 PET imaging to assess microglia activation

    Also known as: TSPO PET imaging

  • Diagnostic test3T MRI

    serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness

  • Diagnostic testimmune cell profiling in blood

    Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.

06

What researchers measure

Primary outcomes

  1. microglia activation in patients with acute stroke

    Microglia activation will be assessed using TSPO PET imgaing.

    Time frame: within 10 days after acute ischemic stroke

  2. microglia activation in patients with acute stroke

    Microglia activation will be assessed using TSPO PET imgaing.

    Time frame: 3 months after acute ischemic stroke

  3. functional outcome in patients after acute ischemic stroke

    Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.

    Time frame: 3 weeks after acute ischemic stroke

  4. functional outcome in patients after acute ischemic stroke

    Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.

    Time frame: 3 months after acute ischemic stroke

  5. functional outcome in patients after acute ischemic stroke

    Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.

    Time frame: 6 months after acute ischemic stroke

  6. functional outcome in patients after acute ischemic stroke

    Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.

    Time frame: 12 months after acute ischemic stroke

  7. cognitive outcome in patients after acute ischemic stroke

    Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.

    Time frame: 3 weeks after acute ischemic stroke

  8. cognitive outcome in patients after acute ischemic stroke

    Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.

    Time frame: 3 months after acute ischemic stroke

  9. cognitive outcome in patients after acute ischemic stroke

    Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.

    Time frame: 6 months after acute ischemic stroke

  10. cognitive outcome in patients after acute ischemic stroke

    Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.

    Time frame: 12 months after acute ischemic stroke

Secondary outcomes

  1. inflammatory markers in blood

    Inflammatory markers in blood will be assessed by flow cytometry and related to microglial activation.

    Time frame: 3 weeks after acute ischemic stroke

  2. inflammatory markers in blood

    Inflammatory markers in blood will be assessed by flow cytometry and related to microglial activation.

    Time frame: 3 months after acute ischemic stroke

  3. Duplex ultrasound

    Duplex ultrasound will be performed to assess potential progress of atherosclerosis related to inflammatory markers

    Time frame: 6 months after acute ischemic stroke

  4. 3T MR imaging

    3T MRI will be performed to relate infarct evolution, secondary neurodegeneration, and stroke outcome to microglial activation.

    Time frame: 3 months after acute ischemic stroke

  5. 3T MR imaging

    3T MRI will be performed to relate infarct evolution, secondary neurodegeneration, and stroke outcome to microglial activation.

    Time frame: 12 months after acute ischemic stroke

07

Study locations

2 of 2 sites recruiting
  • Department of Nuclear Medicine
    Munich, 81377, Germany
    Recruiting
  • Insitute for Stroke and Dementia Research
    Munich, 81377, Germany
    Recruiting
    • Martin Dichgans, Prof. · Contact+49 89 4400
    • Anna Kopczak, MD · Contact+49 89 4400
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Dec 2026, 77 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 77 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2020
First posted
Jun 2, 2020
StartActual
Jul 1, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04412187
Lead sponsor
Martin Dichgans
Responsible party
Martin Dichgans (Prof. Dr. Martin Dichgans, Ludwig-Maximilians - University of Munich) — Sponsor-investigator
First posted
Jun 2, 2020
Start date
Jul 1, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 4, 2025

Study contacts

Martin Dichgans, Prof.
Contact
martin.dichgans@med.uni-muenchen.de
+49 4400 ext. 46019
Anna Kopczak, MD
Contact
anna.kopczak@med.uni-muenchen.de
+49 4400 ext. 46125
Martin Dichgans, Prof.
principal investigator · LMU Munich
Peter Bartenstein, Prof.
principal investigator · LMU Munich
Sibylle Ziegler, Prof.
principal investigator · LMU Munich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion